Evaluation of Thiosulfate in End Stage Renal Disease and Kidney Transplantation

• ClinicalTrials.gov Identifier: NCT04292184
• Recruitment Status: Enrolling by invitation
• First Posted: March 3, 2020
• Last Update Posted: October 8, 2021
• Sponsor: Lawson Health Research Institute
• Information provided by (Responsible Party): Alp Sener, Lawson Health Research Institute

Tracking Information

• First Submitted Date: May 23, 2019
• First Posted Date: March 3, 2020
• Last Update Posted Date: October 8, 2021
• Actual Study Start Date: March 21, 2021
• Estimated Primary Completion Date: November 2022 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: February 27, 2020)

• Patient urine output [ Time Frame: 1 week ]
  1 week following transplant
• Change in Patient urine output [ Time Frame: 1 year ]
  between 1 week and 1 year following transplant
• Serum Creatinine [ Time Frame: 1 week after transplant ]
  Patient Blood serum creatinine results
• Slow Graft Function [ Time Frame: 1 week after transplant ]
  Patients' Rate of slow graft function
• eGFR [ Time Frame: 1 week after transplant ]
  Patient eGFR Results

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: February 27, 2020)

• Biopsy proven Acute tubular necrosis (ATN) [ Time Frame: 1 week ]
  Measuring death of tubular epithelial cells that form the renal tubules of the kidneys.
• Urine protein/creatinine ratio [ Time Frame: 1 week ]
  Patient Urine protein/creatinine ratio results
• Urinary injury biomarkers (KIM-1/NGAL). [ Time Frame: 1 week ]
  Patient urinary injury biomarkers (KIM-1/NGAL).

• Original Secondary Outcome Measures: Same as current
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Evaluation of Thiosulfate in End Stage Renal Disease and Kidney Transplantation
• Official Title: Evaluation of Thiosulfate in End Stage Renal Disease and Kidney Transplantation
• Brief Summary: Kidneys retrieved from deceased donors will be randomized for conventional perfusion (University of Wisconsin: UW) with or without supplementation of thiosulfate, a major H2S metabolite, and transpl anted thereafter. Recipient's renal function will be assessed prospectively to determine if thiosulfate improves allograft function.

Detailed Description

The rise in the incidence of end stage renal disease (ESRD) is both a national and international concern. Renal transplantation is currently the best available treatment for established renal failure as it not only offers freedom from dialysis but improves survival, provides better quality of life and is more cost effective.1 Unfortunately there is a widening discrepancy between the incidence of ESRD and the number of available organs for transplantation. The number of organs available from these donors has never been sufficient for all of the patients on the transplant waiting lists. Over the past decade, donation after cardiac death (DCD) has gained popularity as a method to increase the number of organs available for transplantation. As expected, our attempts at maximizing usable organs for transplant with DCD kidneys comes at a price with a higher risk of delayed graft function (DGF) and graft loss compared to kidneys from standard criteria donors.2 Given that the DCD group is inherently plagued by longer warm ischemic times and labile cardiovascular physiology at the time of the donor operation, up to 30% of recipients of DCD kidneys lose their renal grafts within 5 years and up to 50% in 10 years.3,4 This results in up to 25% of those patients going back onto renal replacement therapies and then becoming relisted for transplantation. If current trends continue, the deficit in organ allocation is expected to rise over the next 20 years due to projected global incidences of obesity, diabetes and hypertension5, which will lead to an increased use of organs procured from increasingly marginal donors to keep up with the demand.

Ischemia reperfusion injury (IRI) is a complex biological process involving cell death, microcirculatory compromise, altered transcription, inflammation and immune activation. Modulation of IRI particularly in DCD organs (characterized by prolonged warm ischemia followed by periods of long hypothermic storage), could impact both short and long term patient and graft outcomes. Importantly, IRI affects all donor kidneys, but the effect appears to be greatest in the DCD cohort. Indeed, significant efforts have been applied in the experimental and pre-clinical setting to develop strategies to ameliorate the negative effects of IRI.

However, there is currently no active pharmacological agent used during transplantation to reduce the impact of IRI. Efforts to curb IRI during transplantation have involved either pulsatile (machine perfusion) or static storage of donor kidneys in various preservation solutions at hypothermic (4ºC) conditions during the peri-transplant period. Hypothermia slows cellular metabolism and subsequent ATP depletion during the ischemic period, while organ preservation solutions contain a myriad of electrolytes and other solutes which help to maintain osmotic conditions, scavenge free radicals and stimulate cellular metabolism upon reperfusion. University of Wisconsin (UW) solution is the most commonly used preservation solutions that has been shown to be the most effective at decreasing the risk of DGF following renal transplantation.6 H2S has long been known for its unsavory "rotten eggs" smell and toxic effects at high concentrations. However, it has been later discovered that H2S is also produced endogenously in mammalian cells mainly via the metabolism of L-cysteine by two cytosolic enzymes, cystathionine ß-synthase (CBS) and cystathionine -lyase (CSE) and one mitochondrial enzyme, 3-mercaptopyruvate sulfurtransferase (3-MST).

Various H2S donation strategies have been developed and tested in vitro and in vivo. The two most often used salts NaHS and Na2S, are among the simplest sources of H2S. They dissociate very rapidly at physiological pH to generate H2S. The resulting bolus of instantly generated H2S does not mimic the endogenous, constitutive enzymatic synthesis of small amounts of H2S.7-9 Another possibility is the use of sodium thiosulphate (Na2S2O3, STS), a major metabolite of H2S, commercially available compound and typically available as the pentahydrate, Na2S2O3·5H2O. It also has functions as a preservative in table salt (less than 0.1 %) and alcoholic beverages (less than 0.0005 %). While these amounts are very small, they indicate that the general population is consuming STS (Sodium thiosulfate) on a regular basis and increasing the dose may have important therapeutic applications, especially in ESRD and chronic kidney disease patients.

In clinical studies, STS has been used in the treatment of some rare medical conditions including calciphylaxis in hemodialysis patients with end-stage kidney disease10,11. Moreover, short term therapeutic use of STS has been proven safe12. STS is also proposed to be an antioxidant10 and HC-approved for use in cyanide poisoning13,14or cisplatin toxicity15. Furthermore, vasodilating properties of STS itself have been described16. However, the effect of STS on the protection of kidney injury and renal graft function post transplantation has not been described clearly. We hypothesize that supplementation of preservation solutions with STS will inhibit IRI injury, improve renal function and graft survival in kidney transplant recipients and that this effect will be heightened in recipients receiving kidneys obtained from DCD donors.

• Study Type: Interventional
• Study Phase: Phase 1

Study Design

Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

For the purposes of this study we will flush the deceased donor kidney with UW (perfusion solution) or UW + sodium thiosulfate (STS). There will be two groups in the study - UW with or without STS and patients will be randomly assigned to a group in a 1:1 ratio (i.e. 50 in one group and 50 in the other).

Masking: None (Open Label)
Primary Purpose: Treatment

• Condition: End Stage Renal Disease (ESRD)

Intervention

Drug: Seacalphyx (sodium thiosulfate pentahydrate injection BP) 25%

The kidney will have 100 mL of 500µM STS added directly to the existing pulsatile perfusion solution at 4°C.

Other Name: Sodium thiosulfate (STS)

Study Arms

• Active Comparator: UW (perfusion solution) + sodium thiosulfate (STS)
  We will flush the deceased donor kidney with UW (perfusion solution) + sodium thiosulfate (STS)
  Intervention: Drug: Seacalphyx (sodium thiosulfate pentahydrate injection BP) 25%
• No Intervention: UW (perfusion solution)
  Kidney will be flushed with UW (perfusion solution) which is the normal standard of care.

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Enrolling by invitation
• Estimated Enrollment (submitted: February 27, 2020): 100
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: November 2023
• Estimated Primary Completion Date: November 2022 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

- All patients >18years old who are being considered for renal transplantation at LHSC that are receiving a DCD kidney.

Exclusion Criteria:

• Age <18 years old
• Inability to give informed consent,
• Patients receiving kidneys from living donors
• Patients with known hypersensitivity to either SEACALPHYX or to any of the ingredients contained within.
• Pregnant women.
• Patients with sulfite allergies

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Canada

Administrative Information

• NCT Number: NCT04292184
• Other Study ID Numbers: 112145
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: Alp Sener, Lawson Health Research Institute
• Original Responsible Party: Same as current
• Current Study Sponsor: Lawson Health Research Institute
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Principal Investigator: Alp Sener, Dr.; LHSC

• PRS Account: Lawson Health Research Institute
• Verification Date: October 2021